NPC's Podium and Poster Presence at AcademyHealth's 2023 Annual Research Meeting
Join NPC at this year's AcademyHealth 2023 Annual Research Meeting, where we will participate in a podium session, Meet-the-Experts Student Breakfast, and poster presentation.
NPC's presence at the AcademyHealth 2023 Annual Research Meeting (ARM):
- Podium Special Session: "The 340B Drug Pricing Program: How Are Its Discounts Helping Vulnerable Patients"
Discussant, John M. O'Brien, PharmD, MPH, National Pharmaceutical Council (Sunday, June 25 from 1:45 p.m. - 3:15 p.m. PT) - Meet-the-Experts Student Breakfast (NPC co-sponsorship)
John M. O'Brien will be an expert and share career advice during this one-hour student networking event. - Poster: "Unintended Consequences of the Inflation Reduction Act: Post-Approval Clinical Development," presented by National Pharmaceutical Council Research Associate James Motyka, PharmD (Monday, June 26 from 2:45 p.m. - 4:00 p.m. PT)
More information is below
The 2023 AcademyHealth Annual Research Meeting (ARM) will be held in person at the Seattle Convention Center in Seattle, Washington. The ARM will convene a large and diverse group of stakeholders at the intersection of health, health care, and policy to share important findings and showcase the latest research on how the health system works, what it costs, and how to improve it.
Sunday, June 25 | 1:45 p.m. - 3:15 p.m. PT
The 340B Drug Pricing Program: How Are Its Discounts Helping Vulnerable Patients
The 340B Drug Pricing Program: How Are Its Discounts Helping Vulnerable Patients
Session Type: Podium Special Session (613-614; Level 6, Seattle Convention Center)
Session Description: In 1992 the 340B Drug Pricing Program was enacted. It requires manufacturers to give certain providers discounts on outpatient drugs and is intended to enable 340B providers to stretch resources in order to reach more eligible patients and provide more comprehensive services. Critics point out its lack of transparency and accountability requirements to ensure savings from drug discounts benefit vulnerable patients. This panel explores whether and how the program has aided vulnerable patients.
Discussant: John O'Brien, PharmD, MPH, National Pharmaceutical Council
Speakers:
- Melissa Morley, PhD, Avalere Health
- Donald Nichols, PhD, Genentech
- Sayeh Nikpay, PhD, MPH, University of Minnesota School of Public Health
Sponsor: Supported in part by Genentech
Monday, June 26 | 7:45 a.m. - 8:45 a.m. PT
Meet-the-Experts Student Breakfast (Sheraton Grand Seattle hotel)
Meet-the-Experts Student Breakfast (Sheraton Grand Seattle hotel)
On Monday, June 26, Dr. John M. O'Brien is pleased to join the annual roundtable "Meet-the-Experts" Breakfast for students. NPC is a co-sponsor of this one-hour student networking opportunity.
Monday, June 26 | 2:45 p.m. - 4:00 p.m. PT
Poster Title: Unintended Consequences of the Inflation Reduction Act: Post-Approval Clinical Development
Poster Title: Unintended Consequences of the Inflation Reduction Act: Post-Approval Clinical Development
Objectives: To describe the landscape of post-FDA (Food and Drug Administration) approval clinical development for high-spend Medicare Part D small molecule drugs and illustrate the potential impact of the Inflation Reduction Act (IRA) on research and development (R&D) investments towards subsequent indications. Click here to view the poster.
Presenter:
- James Motyka, PharmD, Research Associate, National Pharmaceutical Council
Authors:
- Julie Patterson, PharmD, PhD, National Pharmaceutical Council
- Sharon Phares, PhD, MPH
- John O'Brien, PharmD, MPH, National Pharmaceutical Council
Learn More
For agenda, speaker and registration information, visit the AcademyHealth 2023 ARM website.